GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (NAS:LRMR) » Definitions » EPS without NRI

Larimar Therapeutics (Larimar Therapeutics) EPS without NRI : $-0.96 (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Larimar Therapeutics EPS without NRI?

Larimar Therapeutics's earnings per share without non-recurring items for the three months ended in Mar. 2024 was $-0.27. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.96.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 38.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Larimar Therapeutics's EPS without NRI or its related term are showing as below:

LRMR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 18.3   Med: 28.3   Max: 38.3
Current: 38.3

During the past 5 years, Larimar Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 38.30% per year. The lowest was 18.30% per year. And the median was 28.30% per year.

LRMR's 3-Year EPS without NRI Growth Rate is ranked better than
85.51% of 1297 companies
in the Biotechnology industry
Industry Median: 5.5 vs LRMR: 38.30

Larimar Therapeutics's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.27. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.96.

Larimar Therapeutics's EPS (Basic) for the three months ended in Mar. 2024 was $-0.27. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.96.


Larimar Therapeutics EPS without NRI Historical Data

The historical data trend for Larimar Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Larimar Therapeutics EPS without NRI Chart

Larimar Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
-2.51 -3.57 -2.95 -1.37 -0.84

Larimar Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.15 -0.19 -0.21 -0.29 -0.27

Competitive Comparison of Larimar Therapeutics's EPS without NRI

For the Biotechnology subindustry, Larimar Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Larimar Therapeutics's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Larimar Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Larimar Therapeutics's PE Ratio without NRI falls into.



Larimar Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Larimar Therapeutics  (NAS:LRMR) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Larimar Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Larimar Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Larimar Therapeutics (Larimar Therapeutics) Business Description

Traded in Other Exchanges
Address
Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Executives
Gopi Shankar officer: Chief Development Officer C/O LARIMAR THERAPEUTICS, INC., THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA 19004
Jeffrey W Sherman director C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Russell Clayton officer: Chief Medical Officer 2600 KELLY RD, WARRINGTON PA 18976
Carole Ben-maimon director, officer: President and CEO C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Michael Celano officer: Chief Financial Officer 220 EAST FIRST STREET, BETHLEHEM PA 18015
Joseph Truitt director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Thomas Edward Hamilton director 211 STUYVESANT AVE, RYE NY 10580
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Jonathan S Leff director C/O DEERFIELD MANAGEMENT COMPANY, L.P, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Mgmt Hif, L.p. director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Chondrial Therapeutics Holdings, Llc 10 percent owner 150 MONUMENT ROAD, SUITE 207, BALA CYNWYD PA 19004
Deerfield Mgmt Iv, L.p. director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iv, L.p. director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017
Deerfield Healthcare Innovations Fund, L.p. director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Mgmt Iii, L.p. director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017